Greenwich LifeSciences Announces Plan to Build Out Internal Clinical Operations Team
1. GLSI is enhancing internal management for Phase III trial, FLAMINGO-01. 2. This move will reduce costs and improve clinical trial efficiency. 3. The company aims to open up to 150 clinical sites globally. 4. Internal team allows for simultaneous trials and future study expansions. 5. CEO asserts strategy will lower burn rate while ensuring data quality.